{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_references_citation in Reference Text / Citation (approximate match)
Status:
Other
Class:
POLYMER
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(20) weight control maltodextrin
Source URL:
First approved in 1984
Source:
NeuroBion by BENARD INDUSTRIES INC
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 346
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Novipet by Novipet, Inc.
(2012)
Source URL:
First approved in 2012
Source:
Novipet by Novipet, Inc.
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Remaxazon External Patch by Home Aide Diganostics, Inc.
Source URL:
First approved in 2012
Source:
21 CFR 347
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2019)
Source URL:
First approved in 2010
Source:
21 CFR 348
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2014)
First approved in 2006
Source:
GARDASIL by MERCK AND CO INC DIV MERCK SHARP AND DOHME
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2013)
First approved in 1942
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04353518: Phase 3 Interventional Unknown status COVID-19
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
